期刊文献+

慢性阻塞性肺疾病合并意识障碍患者血清IFN-γ、IL-1β、NO水平变化的临床意义 被引量:11

The clinical significance for changes of serum IFN-γ,IL-1β and NO in patients with chronic obstructive pulmonary disease merging conscious disturbance
下载PDF
导出
摘要 目的:探讨干扰素γ(IFN-γ)、白介素1β(IL-1β)及一氧化氮(NO)在慢性阻塞性肺疾病(COPD)合并意识障碍中的水平变化及其临床意义。方法:60例COPD合并意识障碍患者作为治疗组,以30例健康体检者为对照组,治疗组予以抗炎,止咳平喘等常规治疗,对照组不作处理。以ELISA法测定对照组及治疗组治疗前后的IFN-γ、IL-1β水平,以硝酸还原酶法检测NO水平;测定对照组及治疗组治疗前后动脉血气指标、格拉斯哥评分(GCS)。结果:治疗组治疗前IFN-γ、IL-1β、NO水平显著高于对照组和治疗后组(P<0.05),其动脉血气指标、GCS评分与对照组和治疗后组比较有显著差异(P<0.05)。结论:IFN-γ、IL-1β作为细胞炎症因子可能参与了COPD合并意识障碍的发生发展,降低IFN-γ、IL-1β水平可以下调NO水平,缓解患者的病情,为该病的治疗提供了重要的理论依据。 Objective: To investigate the change and clinical meaning of serum IFN-γ,IL-1β and NO in patients with chronic obstructive pulmonary disease( COPD) merging conscious disturbance. Methods: 98 patients with COPD merging conscious disturbance were regarded as control group. 20 healthy examined people were as normal group. Control group was given anti-inflammatory and relieving cough and asthma therapy. Thus normal group were not treated. Level of serum NO,IFN-γ,IL-1β in each group were tested by ELISA. Arterial blood gas and GCS were also checked. Results: Compared with normal group and non-treatment group,arterial blood gas and GCS of treated group had a significant difference( P 〈 0. 05). Level of serum IFN-γ,IL-1β and NO in treated group were greatly higher than that of normal group and non-treatment group( P 〈 0. 05). Conclusion: As the cell inflammation factor,IFN-γ and IL-1βmay be associated with occurrence and progression of COPD merging conscious disturbance. However the patient’s condition can be released by decreasing level of serum IFN-γ,IL-1β and NO. It offers an important theoretical foundation on therapy for this disease.
出处 《川北医学院学报》 CAS 2014年第6期583-585,共3页 Journal of North Sichuan Medical College
基金 福建省泉州市社会发展计划重点项目(2012Z58)
关键词 慢性阻塞性肺疾病 意识障碍 动脉血气指标 格拉斯哥评分 Chronic obstructive pulmonary disease Conscious disturbance Arterial blood gas Glasgow Coma Scale
  • 相关文献

参考文献13

二级参考文献102

共引文献8273

同被引文献129

  • 1慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67-80. 被引量:2032
  • 2史伟,张良登,宋玉明,张月.参附注射液在脑血管疾病方面的临床应用与实验研究进展[J].中国中医药信息杂志,2009,16(S1):109-111. 被引量:11
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 4慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1794
  • 5Singh VK, Patricia George M, Gries CJ. Pulmonary hypertension is associated with increased post-lung transplant mortality riskin patients with chronic obstructive pulmonary disease EJ]. J Heart Lung Transplant, 2015, 34(3) :424-429.
  • 6Rochat T,Charbonnier F,Plojoux J. New therapeutic approaches in 2014 in pulmonary medicine: COPD, asthma and lung fibro- sis [-J]. Rev Med Suisse, 2015, 11(456-457) :129-132.
  • 7Oruqaj G,Karnati S,Vijayan V,et ah Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a high- er fibrotic response via TGF-13 signaling[J]. ProcNatlAcadSci U S A, 2015, 112(16) :E2048-2057.
  • 8Koh RY, Lim CL, Uhal BD, et al. Inhibition of transforming growth factor-t3 via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis[J]. Mol Med Rep, 2015, 11(5) : 3808-3813.
  • 9Song X, Liu W, Xie S, et al. All-transretinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-131/ Smad3 signaling pathway in rats [J]. Lab Invest, 2013, 93 (11) :1219-1231.
  • 10Hansel NN,Sidhaye V,Rafaels NM,et al. Aquaporin 5 polymor- phisms and rate of lung function decline in chronic obstructive pulmonary diseaseEJ]. PLoS One, 2010, 5(12) :e14226.

引证文献11

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部